Urofollitropin, also known as urofollitropin for injection, is a purified form of follicle-stimulating hormone (FSH) derived from the urine of postmenopausal women. It is primarily used in assisted reproductive technology to stimulate ovarian follicle development in women undergoing fertility treatments. Urofollitropin is characterized by its glycoprotein structure, which consists of two subunits (alpha and beta) that are essential for its biological activity. The substance is typically administered via subcutaneous or intramuscular injection. Its mechanism of action involves binding to FSH receptors in the ovaries, promoting the growth and maturation of ovarian follicles. Urofollitropin is often used in combination with other hormones, such as luteinizing hormone (LH), to enhance its efficacy in stimulating ovulation. The purity and potency of urofollitropin are critical for its therapeutic effectiveness, and it is subject to strict regulatory standards to ensure safety and efficacy in clinical use.

Urofollitropin

97048-13-0: 1-{[19-Amino-7-(2-Amino-2-Oxoethyl)-13-(Butan-2-Yl)-16-(4-Hydroxybenzyl)-10-(1-Hydroxyethyl)-6,9,12,15,18-Pentaoxo-1,2-Dithia-5,8,11,14,17-Pentaazacycloicosan-4-Yl]Carbonyl}Prolylleucylglycinamide, FSH, Fertinex, Fertinorm, Metrodin, Orgafol, Urofollitrophin, Urofollitropin

Urofollitropin is a human follicle-stimulating hormone (FSH) analogue that is used to treat infertility in women. It produces follicular growth by stimulating the production of the epidermal growth factor and increasing mitochondrial membrane potential. Urofollitropin has been shown to increase locomotor activity and stimulate blood sampling. It also shows pharmacokinetic properties such as a short half-life and high clearance rate. Follitropin has been shown to be safe for use in humans, with no adverse effects on fetal bovine or granulosa cells.

CAS 97048-13-0: Urofollitropin

Urofollitropin

Ref: 3D-FU41023